FI111364B - Uusia 1-[5-metaanisulfonamidoindolyyli-2-karbonyyli]-4-[3-(1-metyylietyyliamino)-2-pyridinyyli]piperatsiinin kidemuotoja - Google Patents
Uusia 1-[5-metaanisulfonamidoindolyyli-2-karbonyyli]-4-[3-(1-metyylietyyliamino)-2-pyridinyyli]piperatsiinin kidemuotoja Download PDFInfo
- Publication number
- FI111364B FI111364B FI964114A FI964114A FI111364B FI 111364 B FI111364 B FI 111364B FI 964114 A FI964114 A FI 964114A FI 964114 A FI964114 A FI 964114A FI 111364 B FI111364 B FI 111364B
- Authority
- FI
- Finland
- Prior art keywords
- carbonyl
- methanesulfonamidoindolyl
- methylethylamino
- piperazine
- pyridinyl
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 238000001228 spectrum Methods 0.000 claims abstract description 7
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 6
- 150000008054 sulfonate salts Chemical class 0.000 claims description 26
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 20
- 125000004889 1-methylethylamino group Chemical group CC(C)N* 0.000 claims description 13
- 239000003086 colorant Substances 0.000 claims 2
- ZKJKXGCLZUMGNT-UHFFFAOYSA-N methanesulfonic acid;piperazine Chemical compound CS(O)(=O)=O.C1CNCCN1 ZKJKXGCLZUMGNT-UHFFFAOYSA-N 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 238000010992 reflux Methods 0.000 description 18
- 239000002904 solvent Substances 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000002002 slurry Substances 0.000 description 8
- 239000012458 free base Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 125000004076 pyridyl group Chemical group 0.000 description 5
- 229940098779 methanesulfonic acid Drugs 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010001513 AIDS related complex Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropyl acetate Chemical compound CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 206010020144 Histoplasmosis disseminated Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- UZUODNWWWUQRIR-UHFFFAOYSA-L disodium;3-aminonaphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C1=CC=C(S([O-])(=O)=O)C2=CC(N)=CC(S([O-])(=O)=O)=C21 UZUODNWWWUQRIR-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- -1 p-hydroxyphenyl Chemical group 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22786094A | 1994-04-15 | 1994-04-15 | |
US22786094 | 1994-04-15 | ||
US31178094A | 1994-09-23 | 1994-09-23 | |
US31178094 | 1994-09-23 | ||
PCT/US1995/002166 WO1995028398A1 (en) | 1994-04-15 | 1995-03-01 | Novel crystal forms of 1-[5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-(1-methylethylamino)-2-pyridinyl]piperazine |
US9502166 | 1995-03-01 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI964114A FI964114A (fi) | 1996-10-14 |
FI964114A0 FI964114A0 (fi) | 1996-10-14 |
FI111364B true FI111364B (fi) | 2003-07-15 |
Family
ID=26921831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI964114A FI111364B (fi) | 1994-04-15 | 1996-10-14 | Uusia 1-[5-metaanisulfonamidoindolyyli-2-karbonyyli]-4-[3-(1-metyylietyyliamino)-2-pyridinyyli]piperatsiinin kidemuotoja |
Country Status (26)
Country | Link |
---|---|
US (1) | US6452007B1 (zh) |
EP (1) | EP0755393B1 (zh) |
JP (1) | JP3817261B2 (zh) |
KR (1) | KR100364941B1 (zh) |
CN (1) | CN1147253A (zh) |
AT (1) | ATE207481T1 (zh) |
AU (1) | AU693939B2 (zh) |
CA (1) | CA2184598C (zh) |
CZ (1) | CZ287164B6 (zh) |
DE (1) | DE69523447T2 (zh) |
DK (1) | DK0755393T3 (zh) |
ES (1) | ES2164147T3 (zh) |
FI (1) | FI111364B (zh) |
HU (1) | HU226827B1 (zh) |
IL (1) | IL113162A (zh) |
LV (1) | LV12957B (zh) |
MX (1) | MX9604831A (zh) |
MY (1) | MY116830A (zh) |
NO (1) | NO310024B1 (zh) |
NZ (1) | NZ282211A (zh) |
PL (1) | PL180776B1 (zh) |
PT (1) | PT755393E (zh) |
RU (1) | RU2136677C1 (zh) |
SK (1) | SK282424B6 (zh) |
TW (1) | TW393478B (zh) |
WO (1) | WO1995028398A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4827296B2 (ja) | 1998-06-11 | 2011-11-30 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | デラビルジン錠製剤 |
US6872811B1 (en) | 1998-09-30 | 2005-03-29 | Millennium Pharmaceuticals, Inc. | HRPCa9 and HRPCa10 nucleic acids and polypeptides |
DE102011113749A1 (de) * | 2011-09-14 | 2013-03-14 | Aicuris Gmbh & Co. Kg | Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3565924A (en) | 1968-07-01 | 1971-02-23 | Wisconsin Alumni Res Found | 25-hydroxycholfcalciferol |
US3833622A (en) | 1969-03-17 | 1974-09-03 | Upjohn Co | Crystalline 25-hydroxycholecalciferol hydrate and structurally related compounds |
GB1532682A (en) | 1976-04-27 | 1978-11-22 | Bristol Myers Co | Process for the preparation of cephadroxil |
IL63968A (en) | 1980-10-01 | 1985-10-31 | Glaxo Group Ltd | Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it |
AU654808B2 (en) * | 1989-12-28 | 1994-11-24 | Pharmacia & Upjohn Company | Diaromatic substituted anti-aids compounds |
US5563142A (en) * | 1989-12-28 | 1996-10-08 | The Upjohn Company | Diaromatic substituted compounds as anti-HIV-1 agents |
US5599930A (en) * | 1991-07-03 | 1997-02-04 | The Upjohn Company | Substituted indoles as anti-AIDS pharmaceuticals |
-
1995
- 1995-03-01 DE DE69523447T patent/DE69523447T2/de not_active Expired - Lifetime
- 1995-03-01 DK DK95911842T patent/DK0755393T3/da active
- 1995-03-01 JP JP52695295A patent/JP3817261B2/ja not_active Expired - Lifetime
- 1995-03-01 RU RU96119978A patent/RU2136677C1/ru active
- 1995-03-01 US US08/732,254 patent/US6452007B1/en not_active Expired - Lifetime
- 1995-03-01 KR KR1019960705760A patent/KR100364941B1/ko not_active IP Right Cessation
- 1995-03-01 CN CN95192523A patent/CN1147253A/zh active Pending
- 1995-03-01 HU HU9602857A patent/HU226827B1/hu unknown
- 1995-03-01 PT PT95911842T patent/PT755393E/pt unknown
- 1995-03-01 WO PCT/US1995/002166 patent/WO1995028398A1/en active IP Right Grant
- 1995-03-01 EP EP95911842A patent/EP0755393B1/en not_active Expired - Lifetime
- 1995-03-01 MX MX9604831A patent/MX9604831A/es unknown
- 1995-03-01 CZ CZ19962942A patent/CZ287164B6/cs not_active IP Right Cessation
- 1995-03-01 AT AT95911842T patent/ATE207481T1/de active
- 1995-03-01 PL PL95316688A patent/PL180776B1/pl unknown
- 1995-03-01 CA CA002184598A patent/CA2184598C/en not_active Expired - Lifetime
- 1995-03-01 NZ NZ282211A patent/NZ282211A/en not_active IP Right Cessation
- 1995-03-01 SK SK1229-96A patent/SK282424B6/sk unknown
- 1995-03-01 ES ES95911842T patent/ES2164147T3/es not_active Expired - Lifetime
- 1995-03-01 AU AU35136/95A patent/AU693939B2/en not_active Expired
- 1995-03-17 TW TW084102592A patent/TW393478B/zh not_active IP Right Cessation
- 1995-03-28 IL IL11316295A patent/IL113162A/xx not_active IP Right Cessation
- 1995-03-28 MY MYPI95000766A patent/MY116830A/en unknown
-
1996
- 1996-10-14 FI FI964114A patent/FI111364B/fi not_active IP Right Cessation
- 1996-10-15 NO NO964386A patent/NO310024B1/no not_active IP Right Cessation
-
2002
- 2002-10-24 LV LVP-02-186A patent/LV12957B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8541443B2 (en) | Crystal of diamine derivative and method of producing same | |
DE69814049T2 (de) | Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore | |
CZ178993A3 (en) | Hydrochloride of 5-(2-(4-(1,2-benzothiazol-3-yl)-1-piperazinyl) ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one monohydrate, process of its preparation and pharmaceutical preparations in which such monohydrate is comprised | |
CN106831605B (zh) | 一种取代二芳基嘧啶类衍生物及其制备方法与应用 | |
DE69207301T2 (de) | Substituierte 3-Piperazinylalkyl 2,3-Dihydro-4H-1,3-Benzoxazin-4-One, deren Herstellung und Verwendung in Heilkunde | |
EP4201935A1 (en) | Crystal of compound x7 hydrochloride, preparation method therefor and use thereof | |
AU2006319984A1 (en) | Acid addition salt of optically active dihydropyridine derivative | |
FI111364B (fi) | Uusia 1-[5-metaanisulfonamidoindolyyli-2-karbonyyli]-4-[3-(1-metyylietyyliamino)-2-pyridinyyli]piperatsiinin kidemuotoja | |
CN111943889A (zh) | 一种双芳香基胺类化合物及其制备方法和应用 | |
AU2004232495B2 (en) | 4-(4-trans-hydroxycyclohexyl)amino-2-phenyl-7h-pyrrolo [2, 3d]pyrimidine hydrogen mesylate and its polymorphic forms | |
US9145400B2 (en) | Process for the preparation of form III of vilazodone hydrochloride | |
CN113527331B (zh) | 硝基咪唑类衍生物及其制备方法和用途 | |
WO2015186139A2 (en) | Novel polymorphs of tenofovir disoproxil oxalate and process for preparation of the same | |
EP0543307B1 (en) | Nootropic agent | |
JPS62246560A (ja) | 新規なビペラジン誘導体および該化合物を有効成分とする抗潰瘍薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MA | Patent expired |